Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company specializing in bevacizumab treatments for retina diseases, will present at the EURETINA Innovation Spotlight during the 25th EURETINA Congress. The presentation titled "Optimising the treatment of retinal disease" will be delivered by CEO Bob Jahr on September 3, 2025 at 16:10 PM CEST / 10:10 AM EDT in Paris, France.
Outlook Therapeutics (NASDAQ:OTLK), società biofarmaceutica specializzata in trattamenti a base di bevacizumab per le malattie retiniche, presenterà al EURETINA Innovation Spotlight nell'ambito del 25° Congresso EURETINA. L'intervento, intitolato "Optimising the treatment of retinal disease", sarà tenuto dal CEO Bob Jahr il 3 settembre 2025 alle 16:10 CEST / 10:10 EDT a Parigi, Francia.
Outlook Therapeutics (NASDAQ:OTLK), una empresa biofarmacéutica especializada en tratamientos con bevacizumab para enfermedades de la retina, presentará en el EURETINA Innovation Spotlight durante el 25º Congreso EURETINA. La presentación titulada "Optimising the treatment of retinal disease" será impartida por el CEO Bob Jahr el 3 de septiembre de 2025 a las 16:10 CEST / 10:10 EDT en París, Francia.
Outlook Therapeutics (NASDAQ:OTLK)는 망막 질환을 위한 베바시주맙 치료를 전문으로 하는 바이오제약사로, 제25회 EURETINA 총회 기간 중 EURETINA Innovation Spotlight에서 발표합니다. "Optimising the treatment of retinal disease"라는 제목의 발표는 CEO Bob Jahr가 2025년 9월 3일 CEST 기준 오후 16:10 / EDT 기준 오전 10:10에 프랑스 파리에서 진행합니다.
Outlook Therapeutics (NASDAQ:OTLK), entreprise biopharmaceutique spécialisée dans les traitements à base de bévacizumab pour les maladies rétiniennes, présentera au EURETINA Innovation Spotlight lors du 25e Congrès EURETINA. La présentation intitulée « Optimising the treatment of retinal disease » sera donnée par le CEO Bob Jahr le 3 septembre 2025 à 16h10 CEST / 10h10 EDT à Paris, France.
Outlook Therapeutics (NASDAQ:OTLK), ein biopharmazeutisches Unternehmen, das sich auf bevacizumab-basierte Behandlungen von Netzhauterkrankungen spezialisiert hat, wird beim EURETINA Innovation Spotlight während des 25. EURETINA-Kongresses präsentieren. Der Vortrag mit dem Titel "Optimising the treatment of retinal disease" wird von CEO Bob Jahr am 3. September 2025 um 16:10 Uhr CEST / 10:10 Uhr EDT in Paris, Frankreich, gehalten.
- None.
- None.
ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris.
Details for the presentations are as follows:
Session: VEGF Related and Other Retinal Indications
Title: Optimising the treatment of retinal disease
Presenter: Bob Jahr, Chief Executive Officer of Outlook Therapeutics
Date and Time: Wednesday, September 3, 2025, 16:10 PM CEST / 10:10 AM EDT
For more information about this event, please visit EIS 2025.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to optimize the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
FAQ
When is Outlook Therapeutics (OTLK) presenting at EURETINA 2025?
Who will be presenting for Outlook Therapeutics (OTLK) at EURETINA 2025?
What is the topic of Outlook Therapeutics' (OTLK) EURETINA 2025 presentation?
Where is the EURETINA 2025 conference being held?
